2025 Europe Asthma And Copd Drug Market Revenue Opportunities Report
Description
The 2025 Europe Asthma And Copd Drug Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma and COPD drug market in Europe are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK, headquartered in the UK, leads with a broad respiratory pipeline including monoclonal antibodies and long-acting therapies, and has multiple marketed drugs such as Incruse Ellipta and Advair. AstraZeneca offers key COPD treatments like Brimica Genuair and Eklira Genuair with strong growth in Europe. Boehringer Ingelheim is a constant major player with products like Spiriva and Stiolto Respimat, maintaining significant market share in COPD. Novartis also contributes with products like Utibron Neohaler and Seebri Neohaler, expanding its presence in the region.
Additionally, Teva Pharmaceutical Industries and Chiesi Group actively participate in the European market. Chiesi received European authorization for its triple therapy inhaler, NEXThaler, aimed at adult COPD patients. Teva, operating in the UK and Ireland, is also recognized among key market leaders. These companies benefit from Europe's rising awareness, regulatory support, and collaborative efforts to address respiratory diseases, with Europe projected to show the fastest market growth driven by initiatives like the Breathe Vision 2030 program.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Asthma and COPD Drug Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Asthma and COPD drug market in Europe are GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, and Novartis. GSK, headquartered in the UK, leads with a broad respiratory pipeline including monoclonal antibodies and long-acting therapies, and has multiple marketed drugs such as Incruse Ellipta and Advair. AstraZeneca offers key COPD treatments like Brimica Genuair and Eklira Genuair with strong growth in Europe. Boehringer Ingelheim is a constant major player with products like Spiriva and Stiolto Respimat, maintaining significant market share in COPD. Novartis also contributes with products like Utibron Neohaler and Seebri Neohaler, expanding its presence in the region.
Additionally, Teva Pharmaceutical Industries and Chiesi Group actively participate in the European market. Chiesi received European authorization for its triple therapy inhaler, NEXThaler, aimed at adult COPD patients. Teva, operating in the UK and Ireland, is also recognized among key market leaders. These companies benefit from Europe's rising awareness, regulatory support, and collaborative efforts to address respiratory diseases, with Europe projected to show the fastest market growth driven by initiatives like the Breathe Vision 2030 program.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
